Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INO
  • CUSIP: N/A
  • Web:
  • Market Cap: $466.58 million
  • Outstanding Shares: 74,627,000
Average Prices:
  • 50 Day Moving Avg: $7.83
  • 200 Day Moving Avg: $6.96
  • 52 Week Range: $5.83 - $11.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.42
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $37.63 million
  • Price / Sales: 11.92
  • Book Value: $1.42 per share
  • Price / Book: 4.23
  • EBIDTA: ($80,300,000.00)
  • Net Margins: -235.91%
  • Return on Equity: -65.97%
  • Return on Assets: -48.95%
  • Current Ratio: 2.67%
  • Quick Ratio: 2.67%
  • Average Volume: 1.85 million shs.
  • Beta: 2.85
  • Short Ratio: 4.32
Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals's stock reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.31) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.31). The business had revenue of $10.40 million for the quarter, compared to analyst estimates of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company's revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) earnings per share. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

9 brokers have issued 12-month price objectives for Inovio Pharmaceuticals' stock. Their forecasts range from $11.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $22.11 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.

What are analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/11/2017)
  • 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
  • Peter D. Kies, Chief Financial Officer
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer
  • Mark L. Bagarazzi M.D., Chief Medical Officer
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
  • George W. Bickerstaff III, Director
  • David B. Weiner, Director
  • Simon X. Benito, Independent Director
  • Angel Cabrera Ph.D., Independent Director

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Round Table Services LLC (0.17%), Private Capital Advisors Inc. (0.05%) and First Financial Bank Trust Division (0.02%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins, Niranjan Sardesai and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $6.01.

MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  370
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $22.11 (267.91% upside)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
7/7/2017HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
6/8/2017Maxim GroupSet Price TargetBuy$12.00HighView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies Group LLCReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-1.05 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS


Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 27.74%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.20View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
DateHeadline logoInovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : July 20, 2017 - July 21 at 9:03 PM logoMontco immunotherapy company prices $75M stock sale - Philadelphia Business Journal - July 20 at 11:43 PM logoBiotech Movers: Sarepta, Inovio, Mylan - - July 20 at 11:43 PM logoWhy MarineMax, Inovio Pharmaceuticals, and Check Point Software Technologies Slumped Today - Motley Fool - July 20 at 11:43 PM logoBUZZ-US STOCKS ON THE MOVE- IBM, Vertex Pharma, WW Grainger, Scripps Networks, Morgan Stanley - Nasdaq - July 20 at 3:17 AM logoInovio Announces Pricing of Public Offering of Common Stock - Nasdaq - July 20 at 3:17 AM logoHere's Why Inovio Pharmaceuticals, Inc. Stock Fell Today - Motley Fool - July 20 at 3:17 AM logoBRIEF-Inovio Pharmaceuticals says co has about $92 mln of cash and cash equivalents and short-term investments - SEC Filing - July 19 at 10:15 PM logoToday's Research Reports on Trending Tickers: Inovio Pharmaceuticals Inc. and Universal Display Corporation - July 19 at 10:15 PM logoBiotech Movers: Vertex Continues to Move on Data for CF Regimen - July 19 at 10:15 PM logoHere's Why Inovio Pharmaceuticals, Inc. Stock Fell Today - July 19 at 10:15 PM logoInovio Announces Pricing of Public Offering of Common Stock - July 19 at 10:15 PM logoInovio Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release) - July 19 at 7:04 AM logoInovio Pharmaceuticals' (NASDAQ:INO) Buy Rating Reaffirmed at Aegis - July 18 at 1:19 PM logoInovio Pharmaceuticals, Inc. - - July 16 at 11:57 AM logoInovio Pharmaceuticals, Inc. (INO) Rating Increased to Buy at Zacks Investment Research - July 11 at 4:52 PM logoInovio Pharmaceuticals, Inc. (INO) Given Consensus Recommendation of "Buy" by Analysts - July 10 at 8:31 PM logoBiotech Movers: Exelixis, Omeros, Inovio - July 10 at 7:53 PM logoInovio Pharmaceuticals, Inc. (NASDAQ:INO) PT Set at $13.00 by HC Wainwright - July 7 at 6:56 PM logoInovio's Monoclonal Antibody Platform Achieves Proof-of-Principle Validation - July 7 at 6:28 AM logoInovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation - July 7 at 6:28 AM logo Brokerages Anticipate Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Will Announce Earnings of -$0.19 Per Share - July 6 at 12:32 AM logo Brokerages Anticipate Inovio Pharmaceuticals, Inc. (INO) to Announce -$0.19 Earnings Per Share - July 6 at 12:32 AM logoProstate Specific Antigen Pipeline Therapeutics Development Review H1 2017 Says a New Research Report at - June 22 at 11:12 PM logoInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - Nasdaq - June 21 at 3:37 PM logoInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - GlobeNewswire (press release) - June 20 at 2:57 AM logoInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - June 19 at 12:21 PM logoInovio Pharma (INO) Completes Enrollment for Second Zika Vaccine Phase 1 Trial with 160 Subjects in Puerto Rico - June 16 at 5:27 AM logoInovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution - June 16 at 5:26 AM logoWhy Is Inovio (INO) Up 21.3% Since the Last Earnings Report? - June 14 at 11:22 AM logoInovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Buy" from Brokerages - June 13 at 8:52 PM logo3 Stocks That Could Put Amazon's Returns to Shame - June 13 at 5:41 PM logoMaxim Group Analysts Give Inovio Pharmaceuticals Inc (INO) a $12.00 Price Target - June 11 at 8:30 AM logo$18.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter - June 11 at 7:44 AM logoInovio Pharmaceuticals Inc (INO) Expected to Announce Earnings of -$0.19 Per Share - June 10 at 12:28 AM logoCramer’s Exec Cut: CEOs examine the power of strategic pa... - June 9 at 8:24 PM logoInovio Pharmaceuticals Inc (INO) Earns Buy Rating from HC Wainwright - June 9 at 7:38 PM logoInovio's HPV Immunotherapy Moves to Phase III, Stock Rises - June 9 at 9:32 AM logoFDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study - Benzinga - June 8 at 11:58 PM logoWhy Inovio Pharmaceuticals, Inc. Is Rising Today - Motley Fool - June 8 at 11:58 PM logoInovio Pharmaceuticals: Cramer's Top Takeaways - June 8 at 11:58 PM logoBiotech Movers: NewLink, Inovio, Juno - June 8 at 6:52 PM logoWhy Inovio Pharmaceuticals, Inc. Is Rising Today - June 8 at 6:52 PM logoInovio Pharmaceuticals Inc (INO) Upgraded to Overweight by Piper Jaffray Companies - June 8 at 12:22 PM logoFDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study - June 8 at 11:46 AM logoInovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer - June 8 at 6:07 AM logoIs Inovio Pharma's Zika Vaccine the Next Big Thing? - 24/7 Wall St. - June 7 at 10:32 PM logoThese 2 Big Events Pushed Inovio Pharmaceuticals, Inc. Higher by 20% in May - Motley Fool - June 7 at 10:32 PM logoBRIEF-Inovio Zika vaccine prevents persistence of virus and damage in male reproductive tract in pre-clinical study - June 7 at 5:31 PM logoThese 2 Big Events Pushed Inovio Pharmaceuticals, Inc. Higher by 20% in May - June 7 at 11:42 AM



Inovio Pharmaceuticals (INO) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff